BMY - Europe Approves Bristol Myers Squibb's CAR-T Therapy For Early Treatment Of Type Of Blood Cancer | Benzinga
Wednesday, the European Commission approved Bristol Myers Squibb & Co’s (NYSE:BMY) Abecma (idecabtagene vicleucel; ide-cel) for relapsed and refractory multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on the last therapy.
Abecma is the first chimeric antigen receptor (CAR) T cell immunotherapy approved in the European Union for use in earlier lines of therapy for relapsed and refractory multiple myeloma.
Based on the KarMMa-3 study, Abecma is also the first cell therapy approved in Switzerland for the treatment of adult patients with relapsed and refractory multiple myeloma who have ...